Aims: To examine whether undetectable high sensitivity troponin T (hsTnT) can be used to safely rule out non-STelevation acute coronary syndrome (NSTE-ACS) (using the limit of detection (LOD) as the cut-off) and to compare this strategy to serial hsTnT and the use of combined hsTnT and copeptin. Methods: In this prospective observational study, 478 patients presenting with chest pain were consecutively included. A combined primary endpoint of ACS, non-elective revascularization and/or death of all causes was used. The follow-up period was 60 days. Results: NSTE-ACS was diagnosed in 107 (22%) patients during hospital stay. Undetectable hsTnT at admission ruled out NSTE-ACS with a negative predictive value of 94% (95% confidence interval (CI): 88-97) giving a sensitivity of 0.90 (95% CI: 0.80-0.95) versus 0.78 (95% CI: 0.66-0.87) for serial hsTnT testing, p=0.008. The combination of hsTnT and copeptin analysed at admission resulted in a sensitivity of 0.83 (95% CI: 0.74-0.89), p=0.07 for comparison with undetectable hsTnT. Conclusion: A single hsTnT test at presentation, using the LOD as the cut-off, appears to be a safe and time-saving strategy to rule out NSTE-ACS. Further, undetectable levels of hsTnT were associated with an excellent prognosis and none of the patients with undetectable hsTnT were diagnosed with NSTEMI. Together with ECG and clinical assessment this biomarker strategy might permit outpatient treatment of almost one third of the patients we currently admit for observation.
Introduction
Chest pain is a common cause of emergency department (ED) visits and the leading symptom of acute coronary syndrome (ACS). Since ACS is associated with a significant morbidity and mortality, correct diagnosis is of great importance. 1 Despite the use of the present diagnostic cornerstones in the ED (i.e. medical history, physical examination, electrocardiography (ECG) and cardiac troponins), it is a recognized diagnostic challenge to identify all the patients with ACS within the large chest pain population. As a consequence, patients with suspected ACS account for a substantial number of acute medical hospitalizations which subsequently may cause inconvenience for the single patient and large costs for the health care system. 2 The ideal scenario would be to be able to rule out ACS with sufficient accuracy in the ED at presentation. In recent years, many different strategies for such early rule-out have been suggested that are associated with the introduction of the new high sensitivity troponin (hsTn) assays and new biomarkers. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Examples of the proposed strategies are the use of hsTn in combination with a risk score, 4 the use of a second hsTn test analysed after 1 hour, 5 the use of undetectable hsTn levels [6] [7] [8] [9] and the use of a combination of hsTn and another biomarker. [10] [11] [12] [13] [14] [15] [16] In older patients higher hsTn cut-off levels have been suggested to improve diagnostic performance. 17 We have previously reported that the combination of high sensitivity troponin T (hsTnT) and copeptin, a biomarker of endogenous stress, is helpful in the diagnostic process to rule out ACS. [10] [11] [12] [13] [14] Copeptin is the c-terminal of the vasopressin precursor hormone and is co-secreted with the hormone by the neurohypophysis as a response to endogenous stress. 14 One prospective study using the copeptintroponin algorithm has been presented with the results indicating this regimen to be a safe approach. 18 However, if possible, it seems more attractive and easier to use an already established analysis rather than to introduce a new biomarker, and a single hsTn test at admission with a low cut-off therefore emerges as an interesting strategy. Previous studies and a recent meta-analysis have shown that the use of undetectable hsTn renders a very high sensitivity and negative predictive value to rule out acute myocardial infarction (AMI). [6] [7] [8] [9] 19 However, all of these studies have focused on ruling out AMI and not the entire non-STelevation acute coronary syndrome (NSTE-ACS) population including unstable angina pectoris (UA) patients. Some of the studies have also included ST-elevation myocardial infarction (STEMI) patients in which biomarkers are of less value and none of the studies have compared this strategy to any other novel approach. Therefore further studies, with clinically relevant endpoints and including UA patients, comparing different diagnostic strategies are needed.
The aim of this study was to examine whether undetectable levels of hsTnT (with our measurement methodology defined as <5 ng/L) can be used to safely rule out NSTE-ACS in patients presenting with chest pain and to compare the diagnostic performance to serial hsTnT testing (i.e. standard care) and the use of the combination of hsTnT and copeptin. Further, we wanted to test if the diagnostic performance of the various strategies differs in elderly patients (≥70 years old) and how the diagnostic accuracy of hsTnT varies at different cut-offs in the normal range of 5 to 14 ng/L.
Methods

Study site and design
The study was conducted at the Skane University Hospital in Lund, Sweden, from March to July 2011. Patients 18 years or older, with chest pain as the primary symptom and who were admitted for observation for suspected ACS were consecutively included (approximately half of the patients with chest pain in the ED were admitted). Patients with STEMI and patients with no available follow up were excluded. Details about study site, management of patients and definitions of complications are described in an earlier publication. 14 The study was conducted according to the principles of the Declaration of Helsinki and approved by the Regional Ethics Committee in Lund, Lund University (registry number 2010/429). The Regional Ethics Committee did not request informed consent.
Clinical assessment and biochemical analysis
All patients were examined and assessed in accordance with hospital routines. 14 HsTnT was analysed at admission and thereafter mainly every third hour or as long as clinically indicated. Blood samples for copeptin analysis were drawn at admission, frozen and analysed later. The hsTnT method used was Roche high sensitivity troponin T assay and the copeptin method used was BRAHMS copeptin kryptor assay, both previously described. 14 Undetectable hsTnT was defined as values <5 ng/L, which is the limit of detection (LOD) of the current assay; detectable levels were defined as hsTnT ≥5 ng/L. hsTnT values between 5 and 14 ng/L were considered to be in the normal range.
Final diagnosis and follow up
The diagnostic criteria for non-ST-elevation myocardial infarction (NSTEMI) and UA were those defined in current international guidelines. 1, 20 The final diagnosis was set by the authors, blinded for copeptin, using all available data including hsTnT values. 14 UA was defined as a typical chest pain history with either normal or pathological ECG, together with hsTnT values below the 99 th percentile (≤14 ng/L) or elevated hsTnT values without a significant rising or falling pattern. 3 A coronary angiography showing a significant stenosis or a pathological stress test was required to set the final diagnosis of UA. The follow up period was 60 days and a combined primary end point of ACS, non-elective percutaneous coronary intervention or coronary artery bypass surgery and/or death of all causes during this period was used.
Statistical analysis
Continuous variables are presented as medians with the interquartile range and categorical variables are presented as numbers and percentages. Biomarkers were treated as categorical variables. Categorical variables were compared using the Pearson chi-square test or Fisher's exact test if the expected count was low.
A multivariate logistic regression analysis with coronary outcome as the dependent variable and hsTnT as well as other clinically relevant background factors as covariates was performed. 14 The results were presented as odds ratios (OR) with 95% confidence intervals (CI).
Sensitivity, specificity, negative predicative values (NPV) and positive predictive values (PPV) with 95% CI were calculated. Sensitivity and specificity for different diagnostic strategies were compared using the McNemar test. All tests were two tailed and a p-value <0.05 was considered statistically significant. Data management and statistical analyses were performed using IBM SPSS Statistics, version 22.
Results
Patient characteristics and discharge diagnoses
A total of 478 patients were included in this study and 15 were excluded, 10 with STEMI and five with no available follow-up. The median age was 66 years (range 18-96) and 299 (63%) were males. ACS was diagnosed in 107 (22%) patients during hospital stay, 70 (14%) of these had NSTEMI and 37 (8%) had UA. Patients with ACS were older and were more likely to be male with hypertension and hyperlipidemia. Detailed patient characteristics have been described previously. 14 
Logistic regression analysis
Multivariate logistic regression analysis (shown in Table 1 ) indicated that sex (male), hyperlipidemia and detectable hsTnT levels were independently associated with ACS. As expected, hsTnT was by far the most significant predictor of ACS. The OR for ACS in the univariate analysis (Supplementary table 1) was 6.6 (95% CI: 3.3-13.0) in patients with as compared to those without detectable hsTnT and changed only marginally after multivariate adjustment ( Table 1 ). The relatively unchanged OR between the crude and multivariate analysis and hsTnT's very strong association with ACS allowed further statistical analysis of the different diagnostic strategies without adjustment for other variables.
Complications and outcomes
Complications and outcomes during the study period related to hsTnT and copeptin levels are shown in Table 2 . A total of 160 (33%) patients had undetectable hsTnT levels at admission and one of these patients (0.6%) had a serious adverse event compared to 10 (8%) patients (one patient had two different adverse events) with troponin levels in the normal range (p=0.003). Further, 10 (6%) patients with undetectable hsTnT reached the combined primary end point at 60 days (all were of male sex and diagnosed with UA at discharge) compared to 24 (18%) patients with troponin levels in the normal range (p=0.003). None of the patients with undetectable hsTnT levels at admission were diagnosed with NSTEMI during the study period compared to nine (7%) patients with troponin levels in the normal range (p=0.001).
Evaluation of diagnostic strategies
There was at least one follow up sample available in 440 patients, only in 38 (25 men and 13 women) were there only one hsTnT sample analysed at admission. Three hundred and nine patients had a second hsTnT analysed at 3-4 hours (the diagnostic performance of serial hsTnT testing was analysed in this subgroup (see below)) and 131 patients had a follow up sample at a different time, mainly at 6-7 hours. The 38 patients with no available follow up sample either had another obvious diagnosis or underwent early coronary angiography.
The comparison of sensitivity, specificity, NPV and PPV for undetectable hsTnT, hsTnT below the 99 th percentile (≤14 ng/L) and combination of hsTnT and copeptin at admission are shown in Table 3 . The sensitivity for the diagnosis of ACS was significantly higher when using the LOD as the cut-off compared to when using the 99 th percentile as the cut-off (p<0.001). In the NSTEMI subgroup the sensitivity and NPV were 100% when using the LOD as cut off. There was a trend towards higher sensitivity when using the LOD as cut-off compared to the combination of hsTnT and copeptin (p=0.07) but the specificity was significantly lower when using the low hsTnT cut-off (p=0.001).
A second hsTnT analysis performed 3-4 hours after admission was available in 309 patients and the comparison between undetectable hsTnT and serial troponin testing in this subgroup is shown in Table 4 . Both methods had a very high sensitivity in the NSTEMI subgroup and the specificity was significantly higher with serial hsTnT testing. The sensitivity to detect UA was significantly higher when using a single hsTnT with the LOD as cut-off, resulting in a significantly higher sensitivity to identify NSTE-ACS.
A summary of the number of patients diagnosed with ACS, NSTEMI and UA at different hsTnT levels within the normal range is shown in Figure 1 .
Elderly patients and gender differences
The diagnostic performances of the diverse strategies were not different in elderly patients (≥70 years old) with exception for the use of undetectable hsTnT (data not shown). Of 198 patients (41% of the entire study population) in this subgroup only 25 patients had undetectable levels of hsTnT at admission, resulting in a sensitivity of 98% (95% CI: 88-100) and specificity of 16% (95% CI: 11-23) for the diagnosis of ACS, missing only one case of UA. The sensitivity was significantly higher (p=0.04) and the specificity significantly lower (p<0.001) compared to the combination of hsTnT and copeptin. There were 179 (37%) women in this study and 29 (16%) patients were diagnosed with ACS (24 (13%) NSTEMI and five (3%) UA) during hospital stay and a total of 33 (18%) patients reached the primary end point at 60 days. Women were less likely than men to have ACS (p=0.012 for comparison) due to a significantly lower incidence of UA (p=0.002) in this group. No female patient who had an undetectable hsTnT at admission reached the combined primary end point at 60 days.
Discussion
In this prospective observational study, which includes consecutive patients presenting with chest pain, we conclude firstly that the use of a single hsTnT at admission, with the LOD as cut-off, can be used to diagnose/rule out ACS with a sensitivity of 91% (95% CI: 83-95%) and a NPV of 94% (95% CI: 88-97%). We report a sensitivity of 100% (95% CI: 94-100%) and a NPV of 100% (95% CI: 97-100%) for NSTEMI and a sensitivity of 73% (95% CI: 56-86%) and a NPV of 94% (95% CI: 88-97%) for UA. Secondly, the use of a single hsTnT at admission, with the LOD as cut-off, results in a significantly higher sensitivity for ACS than serial hsTnT testing (i.e. standard care) and equivalent sensitivity for ACS as the use of the combination of hsTnT and copeptin. Thirdly, undetectable levels of hsTnT are associated with a very low rate of complications and no deaths. Fourthly, the possibility of exclusion of ACS by using undetectable levels of hsTnT seems to be even better in women and elderly patients than in the entire study population.
This study is the first to compare different biomarker rule-out strategies and to report undetectable levels of hsTnT's diagnostic performance for all NSTE-ACS. The results of this study, which in the NSTEMI subgroup are in line with previous publications, [6] [7] [8] [9] 17, 19, 21 indicates that a single test at presentation allows rule-out of NSTEMI in one third of the patients with a very high accuracy. This is at the cost of a lower specificity but we argue that in the clinical context this in not a great issue as rule-in regardless requires serial hsTnT testing. In this material, the use of a single hsTnT at admission, with the LOD as cut-off, failed to identify 10 patients with UA. All of these patients were men and all but one and had at least one risk factor for coronary artery disease and they were identified by means of history (n=5), ECG (n=2) and/or stress testing (n=3). This emphasizes the importance of using an integrated approach in the diagnosis of ACS, as suggested in the ESC algorithm. 1 It is also important to note that serial testing involves observation time and thereby greater opportunity to work up differential diagnoses which can play an important role in clinical practice.
It has recently been suggested in a randomized trial that cardiac troponin in combination with copeptin can be used to identify patients with suspected ACS in the ED that can safely be discharged with an early follow up. 18 Our study indicates that the use of a single hsTnT at admission, with the LOD as cut-off, has at least the same sensitivity as the combination of hsTnT and copeptin with a slightly lower specificity. The combination of hsTnT and copeptin allows rule-out of 204 (43%) patients, whereas undetectable hsTnT alone allows rule-out of 160 (34%) patients. However, the latter strategy compared to the combination identified eight additional patients with ACS at the cost of 36 more false positives and we argue that this is might be justified in clinical practice. Further, we reason that it is appealing to use an already existing biomarker as a rule-out tool rather than introducing a new analysis that would generate costs, need for education and possibly false positive copeptin values that need to be addressed.
In addition, it has previously been shown that hsTn is a strong independent risk factor for all-cause mortality and adverse cardiovascular events, even at elevated values below the 99 th percentile. 1, [22] [23] [24] [25] [26] We report only one case with a complication in the patients with undetectable hsTnT levels and this patient suffered from ventricular fibrillation hsTnT: high sensitivity troponin T; NPV: negative predictive value; PPV: positive predictive value; ACS: acute coronary syndrome; NSTEMI: non-ST-elevation myocardial infarction; UA: unstable angina pectoris. Sensitivity, specificity, NPV and PPV are given with corresponding 95% CI. High sensitivity troponin T (hsTnT) is presented in the unit ng/L and copeptin in the unit pmol/L. during coronary angiography. By using undetectable levels of hsTnT we might identify a population with a very low risk of adverse events who can safely be handled as outpatients. Further, this study consists of admitted patients and consequently the negative predictive value of an undetectable hsTnT is likely to be even higher in the entire population presenting with chest pain in the ED due to a lower prevalence of ACS in this group. The reason for the good performance of undetectable hsTnT levels to rule-out ACS is primarily due to a better diagnostic performance in the UA subgroup and as shown in Figure 1 it is evident that the number of patients with ACS rises with increasing hsTnT levels in the normal range. These results imply, as suggested in recent reviews, 27-30 that UA with coronary thrombosis and micro embolization might cause some minimal myocardial damage resulting in hsTnT elevations below the 99 th percentile.
Study limitations
Firstly, this is a single centre study, but as our baseline characteristics are comparable to other studies including consecutive admitted patients with chest pain, [6] [7] [8] [9] 17 we consider our results representative for unselected patient cohorts presenting with chest pain.
Secondly, hsTnT elevation and dynamics are part of the diagnosis of ACS and this constitutes a potential source of error to our outcomes. However, since such a large part of our patients (88%) diagnosed with ACS underwent coronary angiography we argue that this has not affected our results significantly.
Thirdly, the diagnosis was set by the authors, blinded for copeptin, using all available data including hsTnT values, and one might argue that the fact that we had access to the troponin values could have affected our outcome. However, the diagnosis was set using definitions in current international guidelines and the processing of the patient data was done well before we raised the question if undetectable hsTnT can be used to safely rule out NSTE-ACS. Since we were "blinded" to the aim of this study when we set the diagnosis and the fact, as mentioned above, that such a large number of our patients underwent coronary angiography we do not believe that an independent review of our diagnoses would change our results significantly.
Fourthly, we have no data on chest pain onset and as previously shown copeptin's supplementary value is greatest early after onset. 12 The clinical value of adding copeptin may therefore be greater in early presenters.
Fifthly, at present there is a more sensitive copeptin assay available which allows a lower cut-off (<10 pmol/L). This copeptin assay was not available to us when we conducted this study and subsequently we have used the then recommended cut-off of 14 pmol/L. It is possible that the use of this newer assay, with a lower cut-off, might improve the diagnostic performance of the combination of hsTnT and copeptin.
Conclusions
A single hsTnT test at presentation, using the LOD as cutoff, appears to be a safe and time-saving strategy to rule out NSTE-ACS. The test fails to identify a small number of patients with UA and we conclude that undetectable hsTnT alone is not sufficient to rule out all NSTE-ACS. However, undetectable levels of hsTnT's excellent rule-out and risk stratification capabilities in addition to a clinical assessment including history and ECG might allow outpatient treatment for almost a third of the patients we currently admit for observation. This could reduce the number of hospitalizations with subsequent lower costs and less inconvenience for the single patient and enable a better use of hospital resources.
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